Journal of Pharmaceutical Research

6-9

Authors: Suresh Arumugam, Senthil Kumar Natesan, Sekar Ganesan, Sumathi Kanagarajan

Purpose: To evaluate the wound healing activity of ethyl acetate fraction of Barleria noctiflora against the STZ induced diabetic rats. Approach: The ethyl acetate fraction of Barleria noctiflora (EAFBN) was evaluated for its wound healing activity in Streptozotocin induced diabetic rats using excision and incision wound models. In case of excision wound model, parameters like wound contraction and period of epithelialization was studied, while in incision wound model, tensile strength of the wound was measured. In incision and excision models, treatment with ointment containing 10% w/w and 5% w/w of EAFBN was done. Findings: The excision wound area exhibited significant (P<0.01) closure of EAFBN 5% w/w and 10% w/w treated animals showed 96.6% and 95.8%, complete epithelialization was observed in same day of EAFBN (10% w/w) and standard drug. In the incision wound model treated with the topical application of EAFBN 5% w/w treated animals skin breaking strength was 290.83±3.0, EAFBN (10% w/w) and standard drug have shown more or less same significant skin breaking strength (342.5 ± 3.81and 350 ± 2.88). Originality: The current study is the first time evaluation of the wound healing activity of Barleria noctiflora ethyl acetate fraction on STZ induced diabetes in rat. The characterization and isolation of the dynamic principle of new compound require broad research in the future. Conclusion: The outcome of present study indicates the usage of ethyl acetate fraction of Barleria noctiflora in the management of wound healing especially in diabetes

15-19

Authors: Bimlesh Chaudhary, Y. Jyothi, S. I. Rabbani

Purpose: To study the potential effect of Asparagus racemosus extract on experimental anemic and thrombocytopenic condition in rats. Approach: The anti-anemic and anti-thrombocytopenic activities of chloroform:methanol (2:1) extract of Asparagus racemosus was studied using phenylhydrazine and heparin-induced models, respectively. Three doses of Asparagus racemosus viz., 250, 500 and 750 mg/kg (p.o, daily for 10 days) were tested in rats, and observations such as levels of RBC count, haemoglobin, mean corpuscular haemoglobin (MCH), WBC, bleeding time and clotting time were recorded. Ferrous sulphate and prednisolone were used as standard agents for anti-anemic and anti-thrombocytopenic activities, respectively. Finding: The anti-anemic study indicated that Asparagus racemosusextract at 750 mg/kg (p<0.01) increase significantly the number of RBC, Hb and significantly decrease (p<0.01) MCH and WBC when compared with anaemic group. In anti-thrombocytopenic study, extract at 750 mg/kg decreased significantly (p<0.01) bleeding time and clotting time compared to heparin group. Our observations indicated that root extract of Asparagus racemosuspossess exhibited anti-anemic and antithrombocytopenic properties and these could be related to the phytoconstituents such as alkaloids, saponins, phytosterols, triterpenoids, polyphenols, carbohydrate, flavonoids, glycosides, phenolic compounds and tannins present in the extract. Originality: The present study is the first time evaluation of the anti-anemic and anti-thrombocytopenic effect of Asparagus racemosus. Conclusion: from our study Asparagus racemosus possess exhibited anti-anemic and antithrombocytopenic properties.